WeiQi MD - Durect Executive Scientist
| DRRX Stock | USD 0.88 0.03 3.30% |
Executive
WeiQi MD is Executive Scientist of Durect
| Address | 10240 Bubb Road, Cupertino, CA, United States, 95014-4166 |
| Phone | 408 777 1417 |
| Web | https://www.durect.com |
Durect Management Efficiency
The company has return on total asset (ROA) of (0.397) % which means that it has lost $0.397 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9988) %, meaning that it created substantial loss on money invested by shareholders. Durect's management efficiency ratios could be used to measure how well Durect manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.74 in 2024. Return On Capital Employed is likely to rise to -1.93 in 2024. At this time, Durect's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 13.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 121.6 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| Vincent Antle | Ligand Pharmaceuticals Incorpor | 55 | |
| Gregory Fuest | Passage Bio | N/A | |
| Andrew JD | Ligand Pharmaceuticals Incorpor | 49 | |
| Michael Jeong | Ligand Pharmaceuticals Incorpor | N/A | |
| Scott MD | Enanta Pharmaceuticals | 50 | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Samantha Prout | Amicus Therapeutics | 46 | |
| Matthew JD | Lyell Immunopharma | 48 | |
| MD FACC | Design Therapeutics | 55 | |
| Srikanth MD | Connect Biopharma Holdings | N/A | |
| Karen MD | Ligand Pharmaceuticals Incorpor | 74 | |
| Patrik Esq | Amicus Therapeutics | N/A | |
| Patrick Lucy | Ligand Pharmaceuticals Incorpor | N/A | |
| Jennifer Viera | Enanta Pharmaceuticals | N/A | |
| Ellen Rose | Lyell Immunopharma | N/A | |
| Kathleen Borthwick | Passage Bio | 47 | |
| Paul Hadden | Ligand Pharmaceuticals Incorpor | N/A | |
| Simon Harford | Amicus Therapeutics | 64 | |
| Sue Browne | Passage Bio | N/A | |
| Todd Pettingill | Ligand Pharmaceuticals Incorpor | N/A | |
Management Performance
| Return On Equity | -3.0 | ||||
| Return On Asset | -0.4 |
Durect Leadership Team
Elected by the shareholders, the Durect's board of directors comprises two types of representatives: Durect inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Durect. The board's role is to monitor Durect's management team and ensure that shareholders' interests are well served. Durect's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Durect's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James DVM, CEO, CoFounder | ||
| Jian MBA, Corporate Finance | ||
| Su Yum, Executive Officer | ||
| Norman MD, Chief Officer | ||
| Keith MBA, Commercial Development | ||
| Timothy MBA, CFO Secretary | ||
| Andrew Miksztal, VP Scientist | ||
| WeiQi MD, Executive Scientist | ||
| Judy Joice, Sr. VP of Operations and Corporate Quality Assurance | ||
| Steve JD, VP Counsel |
Durect Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Durect a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.0 | ||||
| Return On Asset | -0.4 | ||||
| Profit Margin | (1.88) % | ||||
| Operating Margin | (1.57) % | ||||
| Current Valuation | 30.68 M | ||||
| Shares Outstanding | 31.04 M | ||||
| Shares Owned By Insiders | 5.70 % | ||||
| Shares Owned By Institutions | 23.00 % | ||||
| Number Of Shares Shorted | 968.59 K | ||||
| Price To Earning | (3.09) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Durect Stock Analysis
When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.